MedTrace Logo

Predictive Model for High-Flow Nasal Cannula Failure in COVID-19-related Acute Hypoxemic Respiratory Failure Based on Metabolomics and Clinical Data

NCT06695442 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 111

Last updated 2024-11-19

No results posted yet for this study

Summary

The aim of this prospective observational cohort study is to develop a predictive model for high-flow nasal cannula (HFNC) failure in patients with acute hypoxemic respiratory failure (AHRF) caused by SARS-CoV-2. By combining clinical data and metabolomic profiles, the study seeks to answer:

\- Can integrating clinical parameters with metabolomic markers enhance the prediction of HFNC failure in AHRF patients?

Participants with AHRF due to SARS-CoV-2 receiving HFNC under standard-of-care protocols will be monitored until hospital discharge or death. Blood samples for metabolomic analysis will be collected at inclusion.

Conditions

  • Acute Hypoxemic Respiratory Failure
  • COVID 19

Sponsors & Collaborators

  • Fundacio La Marató de TV3

    collaborator UNKNOWN

  • Instituto de Salud Carlos III

    collaborator OTHER_GOV

  • European Union

    collaborator OTHER

  • Hospital del Mar Research Institute (IMIM)

    lead OTHER

Principal Investigators

  • Óscar J Pozo, PhD · Hospital del Mar Research Institute

  • Joan Ramon Masclans Enviz, MD, PhD · Hospital del Mar

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2021-09-30
Completion
2021-12-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06695442 on ClinicalTrials.gov